Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 15 (12) , 861-873
- https://doi.org/10.1097/01213011-200512000-00004
Abstract
The present study investigated CYP2B6 genetic variability by sequencing genomic DNA samples of African-American, Ghanaian, Taiwanese, Japanese and Korean subjects throughout all exons and exon–intron boundaries. The most common nonsynonymous single nucleotide polymorphisms (SNPs) were 15631G>T (Q172H) and 18053A>G (K262R, together defining allele 2B6*6), both of which had frequencies close to 50% in Ghanaians and 30% in African-Americans. These SNPs have recently been shown to affect efavirenz pharmacokinetics and response in HIV patients. Eight new missense mutations (76A>T [T26S], 83A>G [D28G], 85C>A, 86G>C [both R29T], 15618C>T [T168I], 18038G>A [D257N], 21034C>T [R336C], 21498C>A [P428T]), three new silent mutations and two new intronic SNPs defining six novel alleles (*17A and B, *18, *19, *20, *21) were identified. Heterologous expression in COS-1 cells revealed pronounced reduction in expression and/or bupropion hydroxylase activity for variants T168I, D257N, R336C and P428T, whereas the triple mutant 2B6.17 (T26S, D28G, R29T) appeared to be functionally normal. These data extend the CYP2B6 knowledge base and should be particularly relevant for anti-HIV-therapy with efavirenz.Keywords
This publication has 37 references indexed in Scilit:
- A Natural CYP2B6 TATA Box Polymorphism (–82T→ C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start SiteMolecular Pharmacology, 2005
- Efavirenz Intoxication Due to Slow Hepatic MetabolismClinical Infectious Diseases, 2005
- HAPLOTYPE STRUCTURE AND ALLELE FREQUENCIES OF CYP2B6 IN A KOREAN POPULATIONDrug Metabolism and Disposition, 2004
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brainNeuropharmacology, 2003
- Involvement of human liver cytochrome P4502B6in the metabolism of propofolBritish Journal of Clinical Pharmacology, 2001
- A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by AutoactivationBiochemical and Biophysical Research Communications, 2001
- cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liverBiochemistry, 1989